Ameparomo Capsules 250 mg Drug Use Investigation

Brief Title

Ameparomo Capsules 250 mg Drug Use Investigation

Official Title

AMEPAROMO CAPSULES 250 MG DRUG USE INVESTIGATION

Brief Summary

      This Study is intended to evaluate the safety and effectiveness of Ameparomo Capsules 250 mg
      under actual medical practice.
    



Study Type

Observational


Primary Outcome

Number of Participants With Adverse Drug Reactions

Secondary Outcome

 Proportion of Cyst Negative

Condition

Intestinal Amebiasis



Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information



Estimated Enrollment

120

Start Date

October 19, 2015

Completion Date

December 21, 2018

Primary Completion Date

December 21, 2018

Eligibility Criteria

        Inclusion Criteria:

          -  Patients with no history of using this product

        Exclusion Criteria:

          -  No exclusion criteria are set out in this study.
      

Gender

All

Ages

15 Years - 99 Years

Accepts Healthy Volunteers

No

Contacts

Pfizer CT.gov Call Center, , 



Administrative Informations


NCT ID

NCT02680665

Organization ID

B3391001


Responsible Party

Sponsor

Study Sponsor

Pfizer


Study Sponsor

Pfizer CT.gov Call Center, Study Director, Pfizer


Verification Date

December 2019